Reduced-Intensity Allogeneic Stem Cell Transplantation for Co-Emergence of Chemotherapy-Refractory Follicular Lymphoma and Therapy-Related Myelodysplastic Syndrome

A 54-year-old male was diagnosed with follicular lymphoma in September 2003. Despite multiple chemotherapies, including autologous hematopoietic stem cell transplantation (HSCT) with high-dose chemotherapy, the disease eventually relapsed. Additionally, bone marrow analysis revealed the co-emergence...

Descripción completa

Detalles Bibliográficos
Autores principales: Shimura, Yuji, Kuroda, Junya, Sasaki, Nana, Uchiyama, Hitoji, Ohshiro, Muneo, Matsumura, Yayoi, Nagoshi, Hisao, Mizutani, Shinsuke, Kobayashi, Tsutomu, Matsumoto, Yosuke, Horiike, Shigeo, Taniwaki, Masafumi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2014
Materias:
Published online: March, 2014
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3985782/
https://www.ncbi.nlm.nih.gov/pubmed/24748869
http://dx.doi.org/10.1159/000360905
_version_ 1782311626772316160
author Shimura, Yuji
Kuroda, Junya
Sasaki, Nana
Uchiyama, Hitoji
Ohshiro, Muneo
Matsumura, Yayoi
Nagoshi, Hisao
Mizutani, Shinsuke
Kobayashi, Tsutomu
Matsumoto, Yosuke
Horiike, Shigeo
Taniwaki, Masafumi
author_facet Shimura, Yuji
Kuroda, Junya
Sasaki, Nana
Uchiyama, Hitoji
Ohshiro, Muneo
Matsumura, Yayoi
Nagoshi, Hisao
Mizutani, Shinsuke
Kobayashi, Tsutomu
Matsumoto, Yosuke
Horiike, Shigeo
Taniwaki, Masafumi
author_sort Shimura, Yuji
collection PubMed
description A 54-year-old male was diagnosed with follicular lymphoma in September 2003. Despite multiple chemotherapies, including autologous hematopoietic stem cell transplantation (HSCT) with high-dose chemotherapy, the disease eventually relapsed. Additionally, bone marrow analysis revealed the co-emergence of therapy-related myelodysplastic syndrome (t-MDS) in February 2012. In March 2012, we performed related allogeneic HSCT for the treatment of both malignancies. This strategy was successful and the patient has remained free from both malignancies for 23 months. Allogeneic HSCT is a potent curative therapeutic option for both t-MDS and refractory follicular lymphoma.
format Online
Article
Text
id pubmed-3985782
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher S. Karger AG
record_format MEDLINE/PubMed
spelling pubmed-39857822014-04-18 Reduced-Intensity Allogeneic Stem Cell Transplantation for Co-Emergence of Chemotherapy-Refractory Follicular Lymphoma and Therapy-Related Myelodysplastic Syndrome Shimura, Yuji Kuroda, Junya Sasaki, Nana Uchiyama, Hitoji Ohshiro, Muneo Matsumura, Yayoi Nagoshi, Hisao Mizutani, Shinsuke Kobayashi, Tsutomu Matsumoto, Yosuke Horiike, Shigeo Taniwaki, Masafumi Case Rep Oncol Published online: March, 2014 A 54-year-old male was diagnosed with follicular lymphoma in September 2003. Despite multiple chemotherapies, including autologous hematopoietic stem cell transplantation (HSCT) with high-dose chemotherapy, the disease eventually relapsed. Additionally, bone marrow analysis revealed the co-emergence of therapy-related myelodysplastic syndrome (t-MDS) in February 2012. In March 2012, we performed related allogeneic HSCT for the treatment of both malignancies. This strategy was successful and the patient has remained free from both malignancies for 23 months. Allogeneic HSCT is a potent curative therapeutic option for both t-MDS and refractory follicular lymphoma. S. Karger AG 2014-03-13 /pmc/articles/PMC3985782/ /pubmed/24748869 http://dx.doi.org/10.1159/000360905 Text en Copyright © 2014 by S. Karger AG, Basel http://creativecommons.org/licenses/by-nc/3.0/ This is an Open Access article licensed under the terms of the Creative Commons Attribution-NonCommercial 3.0 Unported license (CC BY-NC) (www.karger.com/OA-license), applicable to the online version of the article only. Users may download, print and share this work on the Internet for noncommercial purposes only, provided the original work is properly cited, and a link to the original work on http://www.karger.com and the terms of this license are included in any shared versions.
spellingShingle Published online: March, 2014
Shimura, Yuji
Kuroda, Junya
Sasaki, Nana
Uchiyama, Hitoji
Ohshiro, Muneo
Matsumura, Yayoi
Nagoshi, Hisao
Mizutani, Shinsuke
Kobayashi, Tsutomu
Matsumoto, Yosuke
Horiike, Shigeo
Taniwaki, Masafumi
Reduced-Intensity Allogeneic Stem Cell Transplantation for Co-Emergence of Chemotherapy-Refractory Follicular Lymphoma and Therapy-Related Myelodysplastic Syndrome
title Reduced-Intensity Allogeneic Stem Cell Transplantation for Co-Emergence of Chemotherapy-Refractory Follicular Lymphoma and Therapy-Related Myelodysplastic Syndrome
title_full Reduced-Intensity Allogeneic Stem Cell Transplantation for Co-Emergence of Chemotherapy-Refractory Follicular Lymphoma and Therapy-Related Myelodysplastic Syndrome
title_fullStr Reduced-Intensity Allogeneic Stem Cell Transplantation for Co-Emergence of Chemotherapy-Refractory Follicular Lymphoma and Therapy-Related Myelodysplastic Syndrome
title_full_unstemmed Reduced-Intensity Allogeneic Stem Cell Transplantation for Co-Emergence of Chemotherapy-Refractory Follicular Lymphoma and Therapy-Related Myelodysplastic Syndrome
title_short Reduced-Intensity Allogeneic Stem Cell Transplantation for Co-Emergence of Chemotherapy-Refractory Follicular Lymphoma and Therapy-Related Myelodysplastic Syndrome
title_sort reduced-intensity allogeneic stem cell transplantation for co-emergence of chemotherapy-refractory follicular lymphoma and therapy-related myelodysplastic syndrome
topic Published online: March, 2014
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3985782/
https://www.ncbi.nlm.nih.gov/pubmed/24748869
http://dx.doi.org/10.1159/000360905
work_keys_str_mv AT shimurayuji reducedintensityallogeneicstemcelltransplantationforcoemergenceofchemotherapyrefractoryfollicularlymphomaandtherapyrelatedmyelodysplasticsyndrome
AT kurodajunya reducedintensityallogeneicstemcelltransplantationforcoemergenceofchemotherapyrefractoryfollicularlymphomaandtherapyrelatedmyelodysplasticsyndrome
AT sasakinana reducedintensityallogeneicstemcelltransplantationforcoemergenceofchemotherapyrefractoryfollicularlymphomaandtherapyrelatedmyelodysplasticsyndrome
AT uchiyamahitoji reducedintensityallogeneicstemcelltransplantationforcoemergenceofchemotherapyrefractoryfollicularlymphomaandtherapyrelatedmyelodysplasticsyndrome
AT ohshiromuneo reducedintensityallogeneicstemcelltransplantationforcoemergenceofchemotherapyrefractoryfollicularlymphomaandtherapyrelatedmyelodysplasticsyndrome
AT matsumurayayoi reducedintensityallogeneicstemcelltransplantationforcoemergenceofchemotherapyrefractoryfollicularlymphomaandtherapyrelatedmyelodysplasticsyndrome
AT nagoshihisao reducedintensityallogeneicstemcelltransplantationforcoemergenceofchemotherapyrefractoryfollicularlymphomaandtherapyrelatedmyelodysplasticsyndrome
AT mizutanishinsuke reducedintensityallogeneicstemcelltransplantationforcoemergenceofchemotherapyrefractoryfollicularlymphomaandtherapyrelatedmyelodysplasticsyndrome
AT kobayashitsutomu reducedintensityallogeneicstemcelltransplantationforcoemergenceofchemotherapyrefractoryfollicularlymphomaandtherapyrelatedmyelodysplasticsyndrome
AT matsumotoyosuke reducedintensityallogeneicstemcelltransplantationforcoemergenceofchemotherapyrefractoryfollicularlymphomaandtherapyrelatedmyelodysplasticsyndrome
AT horiikeshigeo reducedintensityallogeneicstemcelltransplantationforcoemergenceofchemotherapyrefractoryfollicularlymphomaandtherapyrelatedmyelodysplasticsyndrome
AT taniwakimasafumi reducedintensityallogeneicstemcelltransplantationforcoemergenceofchemotherapyrefractoryfollicularlymphomaandtherapyrelatedmyelodysplasticsyndrome

Ejemplares similares